Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.
HTLV-1 triggers aggressive forms of leukemia or an incurable spinal cord disease that leads to paralysis: the virus is the often ignored but no less insidious sibling of the HIV virus that causes AIDS and also belongs to the family of retroviruses.
Numerous bacterium types have taken up residence in humans. Currently, research is concentrated on genetically modifying these bacteria to increase their inherent therapeutic qualities.
In humanity's ongoing quest for the elixir of life, the science keeps pointing to stem cells. Research increasingly shows that maintaining stem cell fitness promotes a long healthspan, and new findings show keeping stem cells clean and tidy is an integral step.
Custom-made to attack cancer cells, CAR T-cell therapies have opened a new era in the treatment of human cancers, particularly, in hematologic malignancies.
Scientists from German Cancer Research Center (DKFZ), together with colleagues from Germany, Israel, and the USA, have found that the gut microbiome may modulate the efficacy of CAR-T cellular immunotherapy CAR-T cells in patients with B cell lymphomas.
Microorganisms live in or on almost every part of the human body and play an important role in the regulation of normal human processes. As a result, changes in the number or type of microorganisms, also known as the microbiome, can contribute to disease and altered responses to therapy, including cancer treatment.
Cell division is the process through which the majority of cells in the bodies of living beings duplicate their contents and physically split into new cells.
A new editorial was published in Genes & Cancer on January 19th, 2023, entitled, "Severe herpesvirus infection beats adult T-cell leukemia/lymphoma."
To develop the most efficacious, personalized treatment plans for patients with Hodgkin lymphoma or other cancers, researchers and clinicians must first understand the genetic changes that cause cancer to develop.
The University of Texas MD Anderson Cancer Center and Replay today announced the launch of Syena, a new oncology-focused product company pioneering T cell receptor (TCR) natural killer (NK) cell therapies.
The most detailed study of Hodgkin lymphoma, a type of blood cancer, has offered considerable insight into what tumor cells must do to sustain. The Wellcome Sanger Institute discovered that cancer cells utilize signals to attract specific types of immune cells and direct them not to attack.
Numerous cancers have been related to the viruses Epstein-Barr virus (EBV) and Kaposi sarcoma-associated herpesvirus (KSHV). For the first time, UNC School of Medicine researchers have shown that these viruses elude the innate immune response by using a human protein called barrier-to-autointegration factor 1, or BAF, which enables the viruses to propagate and cause disease.
The Stem Cell and Bone Marrow Transplant Program at Cedars-Sinai Cancer was recently recognized with two important hallmarks of quality: official accreditation for CAR T-cell therapy, and a third year in a row ranking among the top adult bone marrow transplant programs in the U.S.
A MedUni Vienna research group identified a particularly potent biomarker for clinical response to CAR-T cell therapy, establishing the conditions for the most effective use of this innovative therapy for lymphoma treatment.
At the American Society of Hematology (ASH) Annual Meeting in 2022 (Abstract 2016), researchers from the Abramson Cancer Center at the University of Pennsylvania presented preliminary findings from an ongoing Phase I clinical trial demonstrating effective re-treatment with CAR T cell therapy for patients whose cancers relapsed after prior CAR T therapy.
When tested in a lab setting using human cells, a panel of experimental monoclonal antibodies (mAbs) that target various Epstein-Barr virus (EBV) sites prevented infection.
The treatment of various tumors has been transformed by cell-based immunotherapy, often known as CAR-T cell therapy. To target and combat specific forms of leukemia and lymphoma, the treatment employs genetically engineered T cells.
Treatment with chimeric antigen receptor T cells (CAR T cells) is often the last hope for patients with lymphoma, multiple myeloma, or certain kinds of leukemia.
The potential of CAR T-cell therapy for the treatment of solid tumors was unlocked in a preclinical trial by researchers at St. Jude Children’s Research Hospital who discovered a molecular mechanism. The findings were released in the journal Nature.
The interferon-gamma receptor (IFNgR) signaling pathway has been identified to be crucial for the vulnerability of glioblastoma tumors to death by CAR T-cell immunotherapy, according to researchers at Massachusetts General Hospital (MGH).